本帖最后由 老马 于 2012-1-13 21:20 编辑 7 A2 V" {0 ^ w
$ C) q: C X0 e" d
爱必妥和阿瓦斯丁的比较
5 s. Z1 t* c p' t
; M% C& @8 @: E7 S+ Xhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/: D9 g0 [! Y# }
" @2 `; _/ h% N
. d: O, b, {, z& L7 T0 V1 T) @, whttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/' A9 s/ t+ @1 |% O: b& X- w) M
==================================================
, n7 j; A. n9 rOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL); {$ e8 [. O# f; f3 i( T9 n& B
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.* n) n8 X! N, C! f3 K
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.* E9 B$ W) |: d. {. b
|